Pain Studies In The News
Could the hot stuff in chili peppers ease your tingling nerve pain?
October 13, 2009 Source: Health Behavior News Service
A new review suggests, although not strongly, that 4 of 10 people could experience some pain relief from topical capsaicin cream. Capsaicin is the active component of chili peppers. Review studies compared topical capsaicin to either placebo or to another active treatment for pain. In seven of the studies, 41 percent of participants who received the active capsaicin cream experienced “some degree of pain relief, compared to about 26 percent with placebo. [Story]
Physiotherapy helps relieve painful male prostate condition
October 13, 2009 Source: CNW or Canadian Physiotherapy Association
New research regarding the benefits of physiotherapy in treating prostititis is promising. Preliminary studies show that physiotherapy can help relieve the symptoms of prostatitis. It involves correcting muscle imbalances by stretching and strengthening hip and back muscles, stretching of pelvic floor muscles, patient education on pain self-management techniques, and biofeedback. [Story]
More Pain Studies In The News
|
Books:
Complementary and Integrative Medicine in Pain Management
by Michael I. Weintraub, MD, FACP, FAAN, Ravinder Mamtani, MBBS, MD, MSc, and Marc S. Micozzi, MD, PhD
Publishers Description: This book is an invaluable reference for a wide range of health care providers seeking to promote the health and quality of life of patients with chronic pain by employing evidence-based complementary and integrative medicine (CIM) methods.
[More information]
Chronic Pain
by Gary W. Jay, MD.
Chronic Pain is intended to provide a conceptual framework of understanding for anyone who deals with chronic pain patients.
[More information]
Subscribe to The Pain Practitioner!
See sample articles below:
Integrative Pain Management Up Close and Personal – A Visit with Bettina Herbert, MD, by Debra Nelson-Hogan (article)
If you are a member of the Academy, you are entitled to many excellent benefits including The Pain Practitioner, our quarterly magazine. If you are not an Academy member,
you can subscribe for just $35 a year!
[Subscribe!]
Recordings of the Academy's 20th Annual Meeting are Now Available!
Listen to conference presentations in the comfort of your home, office, car, computer, or MP3 player. Individual sessions on CD can be ordered at a cost of $12.00, or purchase the entire conference on CD-ROM with handouts for only $189.00.
Go to www.lawrencemg.com to place an order or call 1-800-466-1962 x7083. |
Stories
Sickle cell anemia complications can be reduced with targeted treatments
October 13, 2009 Source: Geisinger Health System
According to Geisinger physician Dr. Jagadeesh Ramdas, targeted treatments and coping methods are available to ease the pain and reduce the chance for complications in sickle cell anemia. Ramdas believes that if patients and their families are proactive, making a lifelong commitment to using the proper medications and undergoing appropriate treatments, they can learn to cope with the disease and live normal lives. [Story]
The headache center concept: moving beyond a pill or an ice pack
October 6, 2009 Source: Geisinger Health System
Todd Rozen suffered from chronic migraines for more than three decades and it’s his fascination with understanding and treating this chronic condition – and the diminished quality of life that accompanies it – that led him to become a headache specialist. Rozen explains that the goal of the new Geisinger Headache Center is to give options to patients who are frustrated and to offer new avenues to get better and to improve their quality of life. [Story]
More Pain Stories In The News
|
Policy and Law
FDA panel recommends approval of new oxycodone formulation
September 24, 2009 Source: MedPage Today
An FDA advisory panel voted to recommend approval of a new formulation of oxycodone hydrochloride (OxyContin) that is more difficult to crush or dissolve, and which may deter drug abuse. If it's approved, Purdue will produce only the newer version and stop shipping the old one.
[Story]
GAO: Medicaid wastes millions on phony prescriptions for painkillers
October 1, 2009 Source: kaiserhealthnews.org
A new report by the Government Accountability Office found that state and federal officials failed to detect millions of dollars in Medicaid prescription drug abuse. An audit of the government program in five large states found about 65,000 instances of beneficiaries improperly obtaining potentially addictive drugs at a cost of about $65 million during 2006 and 2007 - including thousands of prescriptions written for dead patients or by people posing as doctors.
[Story]
|
Prescription Addiction, Diversion, and Abuse
In 16 states, drug deaths overtake traffic fatals
October 1, 2009 Source: Centers for Disease Control and Prevention
In 16 states and counting, drugs now kill more people than auto accidents do, the government said Wednesday. Experts said the startling shift reflects two opposite trends: driving is becoming safer, and the legal and illegal use of powerful prescription painkillers is on the rise. The drug-related death rate roughly doubled from the late 1990s to 2006, according to the most recent CDC data.
[Story]
Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006
Source: U.S. Centers for Disease Control and Prevention
Drug poisonings are the largest portion of the poisoning burden and opioid analgesic-related deaths are among the fastest increasing drug poisoning deaths. This report highlights trends in fatal opioid analgesic-related poisonings from the years 1999-2006.
[Story]
More Prescription News
|
Product News/Clinical Trial Results
Progenics regains rights to Relistor from Wyeth
October 14, 2009 Source: Progenics Pharmaceuticals Inc®
On Wednesday, Progenics Pharmaceuticals Inc said it reached a deal with Wyeth to regain worldwide rights to Relistor, a medicine used to treat constipation caused by opioid pain drugs. In early 2011, Progenics plans to file an application seeking U.S. approval for use of the product in treating opioid-induced constipation in patients with chronic pain, such as back pain -- a many times larger patient population than for its currently approved use. [Story]
Topline results from Phase 2 clinical trial of oral NKTR-118 presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
October 10, 2009 Source: Nektar Therapeutics
In a Phase 2 double-blind, randomized, placebo-controlled study of 208 patients with opioid-induced constipation, NKTR-118 met the primary endpoint of increase in spontaneous bowel movements over the baseline period. There was no reversal or reduction of opioid-mediated analgesia in any dose groups. NKTR-118 was also well tolerated with the most commonly reported side effects being dose-dependent gastrointestinal-related effects. [Story]
More Product News/Clinical Trial Results
|